Fosfomycin does not inhibit the tumoricidal efficacy of cisplatinum.
OBJECTIVE
This study investigates the effect of fosfomycin on the tumoricidal efficacy of cisplatinum.


METHODS
Prospective study utilizing the FaDu squamous cell carcinoma cell line and a nude mouse tumor xenograft model.


METHODS
Tumor cell growth was assessed in vitro in the presence of cisplatinum and/or fosfomycin utilizing the MTT assay. An optimal cisplatinum dose and dosing schedule was established in a nude mouse tumor xenograft model of squamous cell carcinoma. Using this model, fosfomycin was tested at three dosages and tumor growth monitored over 4 weeks.


RESULTS
Mice treated with cisplatinum and fosfomycin had smaller tumors than those treated with cisplatinum alone (P<.01).


CONCLUSIONS
This study is the first demonstration that fosfomycin does not inhibit the tumoricidal efficacy of cisplatinum in vivo. This suggests that fosfomycin may be useful in preventing cisplatinum-induced ototoxicity and nephrotoxicity in humans without altering the tumor response rate.
Jordan
J A
JA
University of Texas Southwestern, Department of Otolaryngology, Dallas, USA.
Schwade
N D
ND
Truelson
J M
JM
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000009:adverse effects / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004347:Drug Interactions; D005578:Fosfomycin / Q000494:pharmacology*; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced / Q000517:prevention & control; D007674:Kidney Diseases / Q000139:chemically induced / Q000517:prevention & control; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D011446:Prospective Studies; D014407:Tumor Cells, Cultured
D000900:Anti-Bacterial Agents; D005578:Fosfomycin; D002945:Cisplatin